![]() Mimicking catecholamines, beta-2 agonists act as ligands to adrenergic receptors with increased selectivity towards beta-2 adrenergic receptors. This article aims to provide a foundational background of the mechanism of action of beta-2 agonist, the various classifications, and their associated clinical significance and discuss areas of concern and speculations regarding this class of medications.Ĭirculating catecholamines activate adrenergic receptors as part of our functional autonomic system to produce parasympathetic and sympathetic physiological responses. However, since the discovery of beta-2 agonists, there have been many discussions regarding the potential long-term risks versus benefits to the overall rate of morbidity and mortality. Subsequent research aims to improve the efficacy, minimizing adverse effects, with a goal to decrease symptoms, mortality rates, and improve patient quality of life. These new drugs, classified as beta-2 adrenergic receptor agonists, have since become frontline treatments for bronchial asthma and chronic obstructive pulmonary disease (COPD). Pharmacological pursuits turned towards maximizing the selectivity towards the beta-2 receptor in an attempt to reduce the incidence of adverse side effects of the non-selective isoproterenol. ![]() With the discovery of the alpha-1, alpha-2, beta-1, beta-2 receptors in subsequent years, it became known that airway bronchodilation had a strong correlation specifically with beta-2 receptors in the lung vasculature. However, the adverse side effects of isoproterenol became an issue of concern, and the search continued for a treatment with a better side effect profile. The early 1900s marked the advent of epinephrine as a form of treatment in Western medicine after successfully obtaining it from the adrenal gland this became the treatment for asthmatic patients until its replacement in the 1940s with the formulation of isoproterenol, a non-selective beta-adrenoreceptor agonist. Within the last century, there has been extensive research on the bronchodilatory and the anti-bronchoconstrictive properties of these drugs. Thus, the focus of development for this drug class has been mostly on the clinical implications involving their ability to affect those target organ systems. Specifically, the smooth muscle of the airway, uterus, intestine, and systemic vasculature are areas where beta-2 agonists have the greatest effect. They replicate the functions of catecholamines such as epinephrine, norepinephrine, and dopamine in producing different autonomic responses within the body. Beta-2 adrenergic agonists are a drug class used as a mainstay treatment for respiratory diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD).
0 Comments
Leave a Reply. |